Can-Fite BioPharma Ltd is a biotechnology business based in the US. Can-Fite BioPharma shares (CANF) are listed on the NYSE MKT and all prices are listed in US Dollars. Can-Fite BioPharma employs 8 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Can-Fite BioPharma
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – CANF – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
Can-Fite BioPharma stock price (NYSE MKT: CANF)Use our graph to track the performance of CANF stocks over time.
Can-Fite BioPharma shares at a glance
|Latest market close||$2.16|
|52-week range||$1.51 - $3.07|
|50-day moving average||$2.25|
|200-day moving average||$2.19|
|Wall St. target price||$6.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-5.01|
Buy Can-Fite BioPharma shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Can-Fite BioPharma stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Can-Fite BioPharma price performance over time
|1 week (2021-07-19)||N/A|
|1 month (2021-06-30)||-5.26%|
|3 months (2021-04-30)||-0.46%|
|6 months (2021-01-26)||N/A|
|1 year (2020-07-26)||N/A|
|2 years (2019-07-26)||N/A|
|3 years (2018-07-26)||N/A|
|5 years (2016-07-26)||N/A|
Can-Fite BioPharma financials
|Gross profit TTM||$763,000|
|Return on assets TTM||-66.59%|
|Return on equity TTM||-197.23%|
|Market capitalisation||$38.1 million|
TTM: trailing 12 months
Shorting Can-Fite BioPharma shares
There are currently 341,508 Can-Fite BioPharma shares held short by investors – that's known as Can-Fite BioPharma's "short interest". This figure is 13.6% up from 300,534 last month.
There are a few different ways that this level of interest in shorting Can-Fite BioPharma shares can be evaluated.
Can-Fite BioPharma's "short interest ratio" (SIR)
Can-Fite BioPharma's "short interest ratio" (SIR) is the quantity of Can-Fite BioPharma shares currently shorted divided by the average quantity of Can-Fite BioPharma shares traded daily (recently around 742408.69565217). Can-Fite BioPharma's SIR currently stands at 0.46. In other words for every 100,000 Can-Fite BioPharma shares traded daily on the market, roughly 460 shares are currently held short.
However Can-Fite BioPharma's short interest can also be evaluated against the total number of Can-Fite BioPharma shares, or, against the total number of tradable Can-Fite BioPharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Can-Fite BioPharma's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Can-Fite BioPharma shares in existence, roughly 20 shares are currently held short) or 0.0207% of the tradable shares (for every 100,000 tradable Can-Fite BioPharma shares, roughly 21 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Can-Fite BioPharma.
Find out more about how you can short Can-Fite BioPharma stock.
Can-Fite BioPharma share dividends
We're not expecting Can-Fite BioPharma to pay a dividend over the next 12 months.
Have Can-Fite BioPharma's shares ever split?
Can-Fite BioPharma's shares were split on a 1:15 basis on 9 May 2019. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Can-Fite BioPharma shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Can-Fite BioPharma shares which in turn could have impacted Can-Fite BioPharma's share price.
Can-Fite BioPharma share price volatility
Over the last 12 months, Can-Fite BioPharma's shares have ranged in value from as little as $1.51 up to $3.07. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Can-Fite BioPharma's is 1.5507. This would suggest that Can-Fite BioPharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Can-Fite BioPharma overview
Can-Fite BioPharma Ltd. , a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, COVID-19 and erectile dysfunction. The company's lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops CF102 (Namodenoson) that is completed Phase II clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase II trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases.
Stocks similar to Can-Fite BioPharma
Can-Fite BioPharma in the news
Can-Fite Gears Up to Initiate Pivotal Phase III Liver Cancer Study
The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test
Can-Fite Gears Up to Initiate Pivotal Phase III Liver Cancer Study
Frequently asked questionsWhat percentage of Can-Fite BioPharma is owned by insiders or institutions?
Currently 1.068% of Can-Fite BioPharma shares are held by insiders and 12.405% by institutions. How many people work for Can-Fite BioPharma?
Latest data suggests 8 work at Can-Fite BioPharma. When does the fiscal year end for Can-Fite BioPharma?
Can-Fite BioPharma's fiscal year ends in December. Where is Can-Fite BioPharma based?
Can-Fite BioPharma's address is: 10 Bareket Street, Petah Tikva, Israel, 4951778 What is Can-Fite BioPharma's ISIN number?
Can-Fite BioPharma's international securities identification number is: US13471N2018 What is Can-Fite BioPharma's CUSIP number?
Can-Fite BioPharma's Committee on Uniform Securities Identification Procedures number is: 13471N102
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert